Dying to survive: mechanistic insights into human bowel cancer development

Dying to survive: mechanistic insights into human bowel cancer development

Project details

Bowel cancer is major public health problem. Apoptosis is a process of programmed cell death fundamental to normal tissue homeostasis, and defects in this pathway are a hallmark of cancer. This project will study a novel cancer gene candidate for bowel cancer identified in our laboratory, dysregulation of which appears to remodel programmed cell death into a pro-survival pathway driving cell proliferation. 

Work will involve the use of model systems and the analysis of patient cancer specimens. Results will provide fundamental insights into the mechanisms that govern human bowel cancer growth, and may open novel therapeutic opportunities.

About our research group

My research group has a major focus on bowel cancer genomics, the application of high-throughput molecular profiling technologies to identify principal cancer genes, and biomarkers of cancer risk and prognosis. We are conducting next-generation sequencing and microarray studies involving large patient cohorts to define molecular signatures associated with tumour characteristics and outcome.

Patient-focused investigations are being complemented with functional studies on cancer cell lines to distinguish driver from passenger mutations and to gain insights into molecular pathways of carcinogenesis. Molecularly annotated cancer cell lines are further being used to explore the efficacy of novel drug therapies, both as single-agents and in combination with standard therapies.

 

 

Researchers:

Associate Professor Oliver Sieber

Oliver Sieber
Associate Professor
Oliver
Sieber
Acting Division Head

Project Type: